Oxurion Extends Negotiations for French CRO Acquisition

Oxurion NV, a biopharmaceutical company based in Leuven, Belgium, has announced an extension of negotiations for acquiring a majority stake in a French Contract Research Organization (CRO). Initially disclosed on October 13, 2025, the discussions will continue, allowing for further due diligence.

This extension, set for an additional three months, is crucial for validating the target's business plan. Oxurion aims to ensure the prospective acquisition aligns with its strategic goals. The company plans to keep the market updated on any significant developments.

The acquisition aligns with Oxurion's strategy of integrating promising European pharmaceutical subcontractors. The company aims to expand its reach within the healthcare sector.